Anti-GD2 Immunocytokine, IgG (ch14.18)-GM-CSF (ACFP-SH021)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-GD2 IgG to GM-CSF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the GD2 as well as the biological activity of GM-CSF. This antibody-cytokine fusion protein retains the ability to induce ADCC and CDC activity. The fusion of GM-CSF to the antibody increased its cytotoxicity against NMB7 neuroblastoma cells by granulocytes isolated from neuroblastoma patients, and increased ADCC-mediated by mononuclear cells from the same patients, in comparison with ch14.18 alone. This immunocytokine was designed for treating GD2-positive tumors.
Specifications
- Target
- GD2
- Molecule Class
- IgG1-GM-CSF
- Species Reactivity
- Human
- Host
- Chimeric (Human-Mouse)
- Expression Host
- CHO
- Clone
- ch14.18
- Related Disease
- GD2-positive tumors
- Cytokines 1
- GM-CSF
- Cytokines 1 Description
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that functions as a cytokine. The pharmaceutical analogs of naturally occurring GM-CSF are called sargramostim and molgramostim.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- Disialoganglioside GD2; Ganglioside G2; GD2
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: